Validation of DaTscan for Detection of Parkinson Disease Related Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigator initiated trial is designed to measure the accuracy of diagnosis of Parkinson disease through the use of DaTscan. Currently, DaTscan is FDA approved to measure dopamine transporter densities in human tissue. This measurement can assist in distinguishing between Essential Tremor and Parkinsonian Syndromes (idiopathic Parkinson disease, Progressive Supranuclear Palsy, Multi Systems Atrophy, etc). This study will compare both clinical diagnosis of symptoms and the results of the scan to the pathological diagnosis received at time of death. Patients will be registered in the Parkinson Research Institute's brain donation program, receive a clinical diagnosis of Parkinson disease, have their brain scanned using DaTscan, and donate their tissue for research and autopsy purposes. The hypothesis of the study is that DaTscan will diagnosis Idiopathic Parkinson Disease as accurately as a clinician.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism

NCT01358474

Parkinson Disease Gaucher Disease Idiopathic Rapid Eye Movement Sleep Disorder

COMPLETED

A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms

NCT00382967

Parkinsonian Syndromes

COMPLETED PHASE4

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression

NCT00134784

Parkinson Disease

COMPLETED PHASE2

PharmacoMRI of Parkinson Disease

NCT01528592

Parkinson's Disease

COMPLETED NA

Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration

NCT02125825

Parkinson's Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Movement Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

l-123 Ioflupane

Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.

l-123 Ioflupane

Intervention Type DRUG

5 millicuries of Ioflupane

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

l-123 Ioflupane

5 millicuries of Ioflupane

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DaTscan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aged 75 or older
* sporadic late onset Parkinson disease or one of its variants
* registered in tissue donation program

Exclusion Criteria

* aged less than 75 years old
* mental status preventing neuroimaging or transportation to site
* inability to remain "relatively steady" during the scanning procedure

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No